This article is more than 5 years old. Information may no longer be current.
FDA grants approval for Sensar IOL
IRVINE, Calif. — Allergan Inc. received approval from the Food and Drug Administration (FDA) to market the Sensar AR40 foldable acrylic posterior chamber intraocular lens (IOL).
“The approval of the Sensar IOL provides Allergan with an advanced technology product that will enable the company to aggressively pursue a sizeable segment of the ophthalmic surgical foldable IOL market,” according to David E.I. Pyott, Allergan’s president and CEO.
The device has been in use in Europe for several years. Researchers there report that the IOL’s slightly tacky surface appears to produce a good seal with the posterior capsule and significantly reduce capsular shrinkage syndrome [“Sensar demonstrates ‘excellent’ biocompatibility, study shows,” Nov. 15, 1999 issue, page 40].